AGM
PTGX icon

Alpine Global Management’s Protagonist Therapeutics PTGX Stock Holding History

Alpine Global Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,279
Closed -$112K – 354
2022
Q4 		$112K Buy
+10,279
New +$86.7K 0.04% 229

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's PTGX Position: Q1 2023 in Review

Alpine Global Management sold out of Protagonist Therapeutics (PTGX) in Q1 2023, closing a stake of 10,279 shares — an estimated $112K sold.

Alpine Global Management first reported a position in PTGX in Q4 2022 and held it in 1 quarter. The position peaked at $112K in Q4 2022. 137 funds tracked by Wall St. Rank hold PTGX as of Q1 2023.

  • Alpine Global Management reported no remaining Protagonist Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Alpine Global Management sold 10,279 Protagonist Therapeutics shares in Q1 2023, an estimated $112K.
  • Alpine Global Management first reported a position in Protagonist Therapeutics in Q4 2022 and held it in 1 quarter.
  • Alpine Global Management's Protagonist Therapeutics position peaked at $112K in Q4 2022.
  • 137 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2023.

Based on Alpine Global Management's 13F filing for Q1 2023, filed 15 May 2023.